NLS Cobra Biologics

Tony Hitchcock, Technical Director at Cobra Biologics, a Charles River Company, is joined by Karin Agerman, Chief Research and Development Officer at CombiGene, to explore the effects of the latest regulatory guidelines from both a CDMO and drug development perspective. As the scale and number of clinical studies performed using Advanced Therapy Medicinal Products (ATMP’s) […]

The market for the supply of plasmid DNA is a unique and fast expanding one, with suppliers are having to develop their service offerings to reflect changing needs. Whilst there are plasmid therapies and vaccines including COVID-19 vaccines in development, much of the market is for the production of plasmids for the transient production of […]

Cobra Biologics and CombiGene have announced that Cobra has produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01. Critical to assuring ‘life time’ supply of therapeutic, this represents a further milestone in the future commercial manufacture of a drug candidate designed for the treatment of drug-resistant focal […]

Cobra Biologics has announced the company’s expansion of operations at its sites in UK and Sweden. Over the next two years Cobra will invest up to £15m (165m SEK) on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost effective viral vector and DNA plasmid production platforms. The initial phase, will […]

Biotech company Alligator Biosciences has finished its first Phase I clinical trial with the immuno-oncology antibody ADC-1013. CDMO Cobra Biologics has manufactured the antibody as part of the company’s cell line development programme for Alligator. Cobra has developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using their maxXpress service, which harnesses the power […]

Cobra Biologics and Alligator Bioscience extend their drug development partnership. The project will deliver second cell line for manufacture of immuno-oncology antibody ADC-1015 following ADC-1013 success. Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, has been contracted to develop a second cell line for Alligator Bioscience AB (Alligator), a Swedish biotechnology company. Alligator […]